ReviewMolecular neurobiology2025
Targeting O-GlcNAcylation: Novel Therapeutic Strategies for Neurological Disease.
Review in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The regulatory mechanisms and clinical translation potential of RNA-binding protein RALY in tumors.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GlcNAcylation is a crucial post-translational modification. O-GlcNAcylation represents a dynamic monosaccharide modification that exhibits complex crosstalk with other post-translational modifications. It is ubiquitously present in nuclear, cytoplasmic, and mitochondrial proteins, participating in fundamental physiological processes such as cell adhesion and signal transduction. O-GlcNAcylation is particularly abundant in the brain, where it plays critical roles in nervous system development, synaptic plasticity, and energy metabolism. Functioning as both a nutrient sensor and signal integrator, O-GlcNAcylation holds significant importance in both the physiological and pathological processes of the nervous system. The development of pharmacological agents targeting O-GlcNAcylation has emerged as a major research focus. These agents have demonstrated therapeutic potential in animal models, including improving cognitive function, attenuating neuroinflammation, and inhibiting pathological protein aggregation. This review focuses on the roles of O-GlcNAc modification in neurological disorders and summarizes current drug development efforts targeting these conditions, aiming to provide novel perspectives for future research.
Indexed as
Identifiers
41296198What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.